CME Dermatology to overcoming the immunosuppressive tumour environment and boosting
antimelanoma immunity. Overall response rates have been poor in previous studies …

Malignant melanoma is the leading cause of death among cutaneous malignancies. While
its incidence is increasing, the most recent cancer statistics show a small but clear decrease …

Cutaneous melanoma remains a severe public health threat, with annual incidence
increasing slowly but steadily over 4 decades. While early-stage melanomas can typically …

Melanoma is the most aggressive type of skin cancer and is responsible for the majority of
deaths from skin cancer. Therapeutic advances in the last few decades, notably the …

Recent years have seen major improvements in survival of patients with advanced
melanoma with the advent of various novel systemic immunotherapies and targeted …

Arising from melanocytes in skin, mucosal membranes, eye, and meninges, melanoma is a
tumor that has been associated with poor prognosis in advanced disease stages. Given the …

Melanoma is an immunogenic tumor that can induce a natural immune response. A number
of immunotherapy-based approaches have been developed over the past decades, and …

Melanoma is one of the most aggressive cancers and is responsible for a large proportion of
skin cancer-related deaths. The recent development of novel immunotherapeutic …

Single agent dacarbazine (DTIC) has been the standard of care since the 1970s, with
response rates (RRs) between 15% and 20% in advanced MM (4). This is despite no …

Management of malignant melanoma continues to present a challenge to dermatologists,
particularly in advanced cases. In light of the steady increase in the worldwide incidence …